Literature DB >> 22132975

Deoxyribose protects against rapamycin-induced cytotoxicity in colorectal cancer cells in vitro.

I V Bijnsdorp1, G J Peters.   

Abstract

Thymidine phosphorylase (TPase) is also known as the platelet-derived endothelial cell growth factor (PD-ECGF) and plays a role in angiogenesis. Deoxyribose (dR; a downstream TPase-product) addition to endothelial cells may stimulate FAK and p70/S6k signaling, which can be inhibited by rapamycin. Rapamycin is a specific mammalian target of the rapamycin (mTOR) inhibitor, a kinase that lies directly upstream of p70/S6k. This suggests a role for TPase in the mTOR/p70/S6k pathway. In order to study this in more detail, we exposed cells with and without TPase expression to dR and rapamycin and determined the effect on cell growth. We observed protection in cytotoxicity in Colo320 cells, but not Colo320 TP1 cells. This was in part mediated by activation of p70/S6k and inhibition of autophagy. Further studies are recommended to elucidate the mechanism behind the protective effect of dR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22132975     DOI: 10.1080/15257770.2011.602657

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  3 in total

Review 1.  Thymidine phosphorylase: A potential new target for treating cardiovascular disease.

Authors:  Wei Li; Hong Yue
Journal:  Trends Cardiovasc Med       Date:  2017-10-20       Impact factor: 6.677

Review 2.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

3.  Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro.

Authors:  I V Bijnsdorp; Godefridus J Peters
Journal:  Cancer Drug Resist       Date:  2021-05-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.